Subscribe to our Newsletters !!
Infections pose an everpresent threat to society a
In the current world of biotechnology, inefficienc
The Nobel Prize in Physiology or Medicine awarded
Giesen, Germany. 26 January 2026 - At Interpack 20
Alembic Pharmaceuticals Limited (Alembic) today an
Tofu has been a favorite food for vegetarians and
Dear Readers, Welcome to a fresh and forward-lo
Sun Pharmaceutical Industries Limited announced on Thursday that it would purchase Concert Pharmaceuticals of the United States for $576 million in cash in order to gain access to an investigational medication for the treatment of patchy baldness.
Deuruxolitinib, the top contender for Concert, is being studied as a treatment for the autoimmune disorder alopecia areata, which causes patchy hair loss.
Sun Pharma of India said that it will start a tender offer to buy Concert at $8 per share, a premium of 16% over the stock’s most recent finish.
Additionally, contingent value rights will be given to Concert stockholders, entitling them to an extra sum of up to $3.50 per share of common stock in cash, subject to certain sales milestones.
